科研速递论坛

标题: Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresec... [打印本页]
作者: cz_Ryan    时间: 2021-7-7 12:40
标题: Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresec...
题名Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
链接https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00252-7/fulltext

作者: fenavi    时间: 2021-7-7 12:40
  1. https://www.mediafire.com/file/9vg36z8ogywyel4/PIIS1470204521002527.pdf/file
复制代码




欢迎光临 科研速递论坛 (http://expaper.cn/) Powered by Discuz! X2.5